
Brokerage UBS upgrades healthcare conglomerate CVS Health CVS.N to "buy" from "neutral," raising PT to $79 from $67
New PT represents a ~13.2% upside to the stock's last close
Shares of CVS up 2.2% at $70.1 premarket
UBS says CVS has managed its Medicare Advantage plans well, giving the brokerage more confidence in its future performance
UBS believes CVS will reduce its debt by late 2026, allowing for more share buybacks and further earnings growth
UBS says it does not expect any major negative changes from drug pricing rules or its Star ratings in the near term
As of last close, CVS stock up 52.8% YTD